Pros | Among most bought funds within the category. | Among most bought funds within the category. Larger AUM within category. Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | 3Y returns in the bottom 25% of the category. |
INDMoney rank | - | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 2 Years | 12 Years | ||
Fund Size | 1896 Cr | 8114 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹100 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.88% | 0.91% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 31 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (10.47%) Divi's Laboratories Ltd (7.76%) Glenmark Pharmaceuticals Ltd (6.93%) Lupin Ltd (6.84%) Alkem Laboratories Ltd (5.94%) | Sun Pharmaceuticals Industries Ltd (12.29%) Lupin Ltd (7.26%) Divi's Laboratories Ltd (7.01%) Cipla Ltd (6.48%) Apollo Hospitals Enterprise Ltd (5.92%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (97.67%) Basic Materials (2.33%) | Health (100%) | ||
Equity % | 98.97% | 99.47% | ||
Debt % | - | - | ||
P/E | 43.1 | 35.64 | ||
P/B | 6.57 | 5.65 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 3.28% | 3.31% | ||
3-Month Return | -2.01% | -3.31% | ||
6-Month Return | 8.58% | 3.5% | ||
1-Year Return | 7.49% | 0.38% | ||
3-Year Return | - | 21.98% | ||
5-Year Return | - | 19.29% |
Sharpe | - | 0.95 | ||
Alpha | - | -0.21 | ||
Beta | - | 0.91 | ||
Standard Deviation | - | 15.23 | ||
Information Ratio | - | -0.48 |
Description | HDFC Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Dhruv Muchhal,Nikhil Mathur | Sailesh Raj Bhan,Kinjal Desai |